Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Key Points

• Wall Street Zen upgraded Vor Biopharma to “Hold” from “Sell.” Despite mixed recommendations, analysts’ overall consensus remains “Moderate Buy,” with an average price target of $43.38.
• Vor Biopharma’s stock opened at $23.03, above its 50-day and 200-day moving averages, but remains well below its 52-week high of $50.20. The company recently reported a quarterly loss of $0.80 per share, missing the $0.69 loss estimate.
• Institutional investors own 97.29% of the company. Several funds recently initiated or increased positions, while analysts expect Vor to remain unprofitable during the current fiscal year.

Vor Biopharma (NASDAQ:VOR - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

VOR has been the subject of several other research reports. HC Wainwright restated a "buy" rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a research note on Tuesday. Wedbush boosted their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday. Finally, Jefferies Financial Group upgraded shares of Vor Biopharma to a "strong-buy" rating in a research note on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vor Biopharma has an average rating of "Moderate Buy" and a consensus target price of $43.38.

Vor Biopharma Stock Performance

VOR stock opened at $23.03 on Friday. The business has a 50 day moving average price of $18.55 and a 200 day moving average price of $16.01. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $50.20.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Analysts forecast that Vor Biopharma will post -2.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Vor Biopharma during the fourth quarter worth approximately $36,000. Bank of America Corp DE increased its holdings in shares of Vor Biopharma by 679.3% in the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company's stock valued at $232,000 after acquiring an additional 4,144 shares during the period. Squarepoint Ops LLC purchased a new stake in Vor Biopharma in the 3rd quarter valued at $230,000. BNP Paribas Financial Markets raised its position in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock valued at $296,000 after purchasing an additional 5,058 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Vor Biopharma during the 3rd quarter worth $304,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Vor Biopharma

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: Wedbush raised its price target to $27. The higher target provides additional support for the stock’s valuation and reflects continued optimism about Vor Biopharma’s long-term prospects. Wedbush Increases Vor Biopharma Price Target to $27.00
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $31 price target. The firm expects continued losses in the near term, including estimated 2027 EPS of negative $3.65, but projects a return to profitability by 2029 at $1.33 EPS. Its estimates imply that the investment case remains dependent on successful clinical and commercial execution.
• Negative Sentiment: HC Wainwright lowered several future earnings forecasts. The firm reduced its Q3 2026 EPS estimate to negative $0.91 from negative $0.70 and its Q4 2026 estimate to negative $0.94 from negative $0.72. It also cut full-year 2027 EPS to negative $3.65 from negative $2.78, full-year 2028 EPS to negative $2.61 from negative $1.67, and full-year 2029 EPS to $1.33 from $1.86. These revisions suggest higher expected losses and a slower path to profitability.
• Negative Sentiment: Recent quarterly results missed expectations. Vor reported a quarterly loss of $0.80 per share versus the consensus estimate of a $0.69 loss, an unfavorable earnings surprise that pressured the stock. Analysts expect the company to remain unprofitable during the current fiscal year. Vor Biopharma Stock Price Down Following Weak Earnings

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source